We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Bests EMA in Cancer Drug Approval Times, Study Finds
U.S. FDA Bests EMA in Cancer Drug Approval Times, Study Finds
September 10, 2012
The U.S. Food and Drug Administration (FDA) continues to approve cancer drugs more quickly than the European Medicines Agency (EMA), clearing them in about half the time regardless of the drug’s designation, according to a recent study.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor